We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Precigen Inc | NASDAQ:PGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.35 | 1.34 | 1.36 | 0 | 11:37:03 |
From May 2023 to May 2024
By Dean Seal
Precigen said the U.S. Food and Drug Administration has granted breakthrough therapy designation for PRGN-2012 AdenoVerse immunotherapy, its recurrent respiratory papillomatosis treatment.
Shares jumped 10.7% to $1.35 in premarket trading Tuesday.
The breakthrough therapy designation is designed by the FDA to expedite the development and evaluation of treatments for serious or life-threatening conditions if they have preliminary clinical evidence showing substantial improvement at certain endpoints over currently available therapies.
Chief Executive Helen Sabzevari said the designation would allow Precigen to directly engage with the FDA's senior leadership about forging an efficient product development pathway.
"The potential of PRGN-2012 to reduce surgical interventions and improve outcomes for these patients makes us incredibly proud to receive the FDA's Breakthrough Therapy Designation," Sabzevari said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2023 08:06 ET (12:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Precigen Chart |
1 Month Precigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
